Glucagon-Like Peptide-1 (GLP-1) medications have largely been discussed as a pharmaceutical and clinical story. Increasingly, however, they are becoming a healthcare strategy story.
A recent Wells Fargo analysis highlighted by Fierce Healthcare suggests that widespread GLP-1 use could disrupt a healthcare system that has historically invested significant resources in treating the downstream consequences of obesity (Fierce Healthcare, 2026). As treatment moves further upstream, healthcare organizations may need to reconsider everything from service-line projections and utilization patterns to reimbursement, staffing, documentation, and long-term growth strategies.
For hospitals, physician practices, health systems, post-acute providers, behavioral health organizations, payers, and other healthcare stakeholders, the question is no longer simply, “Will GLP-1 utilization continue to grow?”
The more important question may be: What should we be doing differently if it does?
The Shift Is Already Showing Up in Utilization
There are signs that changes are already occurring.
A 2026 study examining more than one million bariatric procedures found that procedure volume declined 23% from its 2022 peak to 2024. Researchers noted that the timing of the decline coincided with rapid adoption of anti-obesity medications, although GLP-1 use is not necessarily the sole cause of changing surgical volumes (Wills, 2026).
Another recent analysis using the Epic Cosmos database found bariatric surgery utilization decreased 39% from its late-2022 peak through the fourth quarter of 2025. At the same time, an increasing percentage of patients undergoing surgery had previously received semaglutide or tirzepatide (Calzaretta, 2026).
That distinction is important. GLP-1 medications may not simply eliminate existing services. They may change who needs them, when they need them, and how patients move through the healthcare system.
For healthcare executives, that has significant implications.
Yesterday’s Revenue Assumptions May Not Be Tomorrow’s
Many healthcare organizations have built programs around conditions associated with obesity, including diabetes, cardiovascular disease, sleep apnea, orthopedic complications, bariatric care, renal disease, and other chronic conditions.
If GLP-1 therapies alter the prevalence, severity, or progression of some of those conditions, organizations may eventually see changes in:
- Procedure and surgical volumes
- Specialty referrals
- Chronic disease management
- Pharmacy utilization
- Diagnostic testing
- Follow-up care
- Population-health programs
- Revenue by service line
- Staffing and provider capacity
- Payer relationships and contracting
That does not necessarily mean disappearing revenue. It may mean different revenue.
Healthcare organizations may need to identify where care is moving and determine whether their operational structure has moved with it.
Reimbursement and Compliance May Become More Complicated, Not Less
Broader access to GLP-1 therapy also introduces reimbursement and compliance considerations.
The Centers for Medicare & Medicaid Services (CMS), for example, began its Medicare GLP-1 Bridge demonstration on July 1, 2026. The program provides certain eligible Medicare Part D beneficiaries access to covered GLP-1 medications for weight management through December 31, 2027. Eligibility depends on specific clinical and coverage criteria, and the program includes prior authorization, claims-processing, and documentation requirements (Centers for Medicare & Medicaid Services, 2026).
That is a reminder of something healthcare organizations know well.
A new treatment option rarely creates only a clinical workflow. It creates an administrative one.
Organizations should be examining whether documentation supports medical necessity, diagnoses are accurately captured, authorization requirements are being followed, clinicians understand payer-specific criteria, and billing processes reflect the services actually being delivered.
Coding accuracy is particularly important when diagnoses and comorbidities affect treatment eligibility, payer policies, risk adjustment, quality reporting, or medical necessity.
The goal should not be to code more. It should be to ensure the record accurately tells the patient’s clinical story.
Healthcare Leaders Should Start Asking Different Questions
Rather than waiting for year-end financial reports to reveal changing utilization, organizations can begin evaluating their exposure now.
Leadership teams should consider questions such as:
What services could be affected?
Identify programs heavily dependent on obesity-related diagnoses, procedures, or complications and evaluate whether utilization patterns are beginning to change.
What does our data tell us?
Review claims, referral patterns, denials, procedure volumes, diagnoses, payer mix, and utilization trends over several years rather than evaluating one quarter in isolation.
Are our coding and documentation practices keeping pace?
New treatment pathways can create new documentation expectations, authorization requirements, and opportunities for coding inconsistencies.
Are patients moving somewhere else in the continuum?
Declining utilization in one area may correspond with increased demand for primary care, medication management, nutrition services, specialty follow-up, behavioral support, remote monitoring, or chronic-care management.
Do our policies and workflows still match current practice?
Clinical innovation often moves faster than policies, procedures, training materials, and revenue-cycle processes.
Does our strategic plan account for changing utilization?
Organizations should be cautious about building future budgets around historical volumes when treatment patterns are changing rapidly.
Where LW Consulting, Inc. Can Help
The GLP-1 story illustrates why healthcare organizations need more than clinical awareness. They need the ability to translate healthcare change into operational action.
LW Consulting, Inc. (LWCI) helps organizations evaluate changing utilization and identify potential compliance, reimbursement, documentation, and operational risks through data and utilization analysis, coding and documentation audits, revenue-cycle reviews, compliance assessments, and strategic consulting.
Healthcare transformation rarely announces exactly where the next vulnerability will appear. It may first show up in utilization, denials, documentation, staffing, or service-line revenue. Identifying those indicators early can help organizations make informed decisions before they become larger problems.
Don’t Just Watch the GLP-1 Trend—Measure Its Impact
GLP-1 medications may ultimately prove to be one of the most significant changes in chronic disease management in recent decades. Their full impact on the healthcare delivery system is still developing.
What healthcare organizations should not do is assume their current operating model will remain unaffected.
Now is the time to examine the data, stress-test assumptions, review compliance and reimbursement processes, and determine whether the organization is prepared for a healthcare environment increasingly focused on preventing or delaying the expensive complications it once routinely treated.
LWCI helps healthcare organizations turn industry change into an actionable plan—identifying risk, improving compliance, strengthening operations, and preparing for what comes next.
LW Consulting, Inc. (LWCI) offers a comprehensive range of services to assist your organization in maintaining compliance, identifying trends, providing education and training, or conducting documentation and coding audits. For more information, contact LWCI to connect with one of our experts!
| Sources: |
| Fierce Healthcare. “GLP-1s Are Forcing a Strategic Reset Across Healthcare: Wells Fargo Report.” August 21, 2026. |
| Centers for Medicare & Medicaid Services. “Medicare GLP-1 Bridge: Expectations and Frequently Asked Questions for Part D Sponsors.” June 10, 2026. |
| Wills, M.V., et al. “Declining Bariatric Surgery Volumes and Shifting Practice Patterns: A Five-Year Analysis of Over One Million Procedures.” Obesity Surgery. July 15, 2026. |
| Calzaretta, R.J., et al. “Trends in Metabolic Bariatric Surgery Utilization in the Era of GLP-1s, 2022–2024.” JAMA Surgery. 2026. |
